Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01)
Research grants that address patient adherence to treatment and prevention regimens to promote positive health outcomes. Clinical trials are optional. Geographic coverage: Nationwide -- National Cancer Institute, National Center for Complementary and Integrative Health, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Nursing Research, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute on Minority Health and Health Disparities, National Institutes of Health, U.S. Department of ...
Source: AIDS and HIV funding opportunities via the Rural Assistance Center - March 28, 2018 Category: Infectious Diseases Source Type: funding
Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-718 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support high risk and high reward basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanisti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2018 Category: Research Source Type: funding
Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)
Funding Opportunity PA-18-719 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2018 Category: Research Source Type: funding
Notice of NIAID's Interest in Continued Support of High Priority Immunology Grants
Notice NOT-AI-18-024 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 28, 2018 Category: Research Source Type: funding
Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-020 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomater...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 14, 2018 Category: Research Source Type: funding
Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.Lisa Spain, Ph.D. | RFA-DK-17-020 (Sou...
Source: NIDDK Funding Opportunities - February 14, 2018 Category: Endocrinology Source Type: funding
Notice of Participation of National Institute of Allergy and Infectious Diseases (NIAID) on PAR-18-333" Understanding the Early Development of the Immune System (R01 - Clinical Trial Not Allowed)"
Notice NOT-AI-18-008 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 18, 2017 Category: Research Source Type: funding
Notice of Change to Award Information in RFA-AI-17-040 "Cooperative Centers on Human Immunology (U19 Clinical Trial Optional"
Notice NOT-AI-18-007 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 18, 2017 Category: Research Source Type: funding
Cooperative Centers on Human Immunology (U19 Clinical Trial Optional)
Funding Opportunity RFA-AI-17-040 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to continue the Cooperative Centers on Human Immunology (CCHI) program to support studies that will advance understanding of the mechanisms regulating human immune responses. The immediate objective of CCHI is to support mechanistic and hypothesis-testing studies to understand human immunity applicable to the biodefense effort; i.e. innate, adaptive and mucosal immune responses to infection, vaccination and adjuvants. Studies on immune-mediated diseases (e.g...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 4, 2017 Category: Research Source Type: funding
Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional)
Funding Opportunity RFA-DK-17-038 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2017 Category: Research Source Type: funding
Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional)
The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection and epidemiological studies of liver ...
Source: NIDDK Funding Opportunities - November 9, 2017 Category: Endocrinology Source Type: funding
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)
Funding Opportunity PA-18-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2017 Category: Research Source Type: funding
Notice of Participation of National Institute of Allergy and Infectious Diseases (NIAID) on RFA-CA-17-031 " Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)
Notice NOT-AI-17-038 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 23, 2017 Category: Research Source Type: funding
NIAID Research Education Program (R25)
Funding Opportunity PAR-17-455 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Allergy and infectious Diseases (NIAID) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in NIAID mission areas. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 11, 2017 Category: Research Source Type: funding
